Synthesis and potent antitumor activities of novel 1,3,5-cis,cis- triaminocyclohexane N-pyridyl derivatives

Journal of Medicinal Chemistry

Volumn 47, Issue 21, 2004, Pages 5230-5234

  Chong, Hyun Soon ^a,c   Torti, Suzy V ^b   Ma, Rong ^b   Torti, Frank M ^b   Brechbiel, Martin W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c Life Science 182   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [[3,5 BIS[(PYRIDIN 2 YLMETHYL)AMINO]CYCLOHEXYLAMINO]METHYL] N [3 [4 (2,5 DIOXO 2,5 DIHYDROPYRROL 1 YL)BUTYRYLAMINO]PROPYL]NICOTINAMIDE; [3 [[6 [[3,5 BIS[(PYRIDIN 2 YLMETHYL)AMINO]CYCLOHEXYLAMINO]METHYL]PYRIDINE 3 CARBONYL]AMINO]PROPYL]CARBAMIC ACID TERT BUTYL ESTER; CYCLOHEXANE DERIVATIVE; IRON CHELATING AGENT; N (3 AMINOPROPYL) 6 [[3,5 BIS[(PYRIDIN 2 YLMETHYL)AMINO]CYCLOHEXYLAMINO]METHYL]NICOTINAMIDE; PYRIDINE DERIVATIVE; TACHPYR; TACHPYR DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SYNTHESIS; HELA CELL; HUMAN; HUMAN CELL; STRUCTURE ANALYSIS; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CYCLOHEXYLAMINES; DRUG SCREENING ASSAYS, ANTITUMOR; HELA CELLS; HUMANS; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4744345552     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040076w     Document Type: Article

References (35)

1. (a) Le, N. T. V.; Richardson, D. R. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim. Biophys. Acta 2002, 1603, 31-46.
2. (b) Richardson, D. R. Iron chelators as therapeutic agents for the treatment of cancer. Crit. Rev. Oncol. Hematol. 2002, 42, 267-281.
3. (c) Kemp, J. D. Iron deprivation and cancer: a view beginning with studies of monoclonal antibodies against the transferring receptor. Histol. Histopathol. 1997, 12, 291-296.
4. (d) Kovar, J.; Stunz, L.; Stewart, B. C.; Kriegerbeckova, K.; Ashman, R. F.; Kemp, J. D. Direct evidence that iron deprivation induces apoptosis in murin lymphoma 38C13. Pathobiology 1997, 65, 61-68.
5. (e) Seligman, P. A.; Schleicher, R. B.; Siriwardana, G.; Domenico, J.; Gelfand, E. W. Effects of agents that inhibit cellular iron incorporation on bladder cancer cell proliferation. Blood 1988, 82, 1608-1617.
6. (f) Trowbridge, I. S.; Lopez, F. Monoclonal antibody to transferring receptor blocks transferring biding and inhibits tumor cell growth in vitro. Proc. Natl. Acad. Sci. U.S.A. 1982, 79, 1175-1179.
7. (a) Richardson, D. R. Iron chelators as therapeutic agents for the treatment of cancer. Crit. Rev. Oncol. Hematol. 2002, 42, 267-281.
8. (b) Liu, M. C.; Lin, T. S.; Sartorelli, A. S. Synthesis and antitumor evaluation of amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone. J. Med. Chem. 1992, 35, 3672-3677.
9. (b) Souron, J.-P.; Quarton, M. Pyrodoxal isonicotinoly hydrazone (PIH), a synthetic iron chelating agent. Acta Crystallogr., Sect. C 1995, 51, 2179-2182.
10. (c) Rakba, N.; Loyer, P.; Gilot, D.; Delcros, J. G.; Glaise, D.; Baret, P.; Pierre, J. L.; Brissot, P.; Lescoat, G. Anti-proliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines. Carcinogenesis 2000, 21, 943-951.
11. (a) Donfrancesco, A.; Deb, G.; DeSio, L.; Cozza, R.; Castellano, A. Role of desferrioxamine in tumor therapy. Acta Haematol. 1996, 95, 66-69.
12. (b) Estrov, Z.; Tawa, A.; Wang, X. H.; Bube, I. D.; Sulh, H.; Cohen, A.; Gelfand, E. W. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood 1987, 69, 757-761.
13. (c) Hann, H. W.; Stahlhut, M. W.; Rubin, R.; Maddrey, W. C. Antitumor effect of deferoxamine on juman hepatocelluar carcinoma growing in athymic nude mice. Cancer 1992, 70, 2051-2056.
14. (d) Cooper, C. E.; Lynagh, G. R.; Hoyes, K. P.; Hider, R. C.; Cammack, R.; Porter, J. B. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J. Biol. Chem. 1996, 271, 20291-20299.
15. (a) Chaston, T. B.; Lovejoy, D. B.; Watts, R. N.; Richardson, D. R. Examination of the antiproliferative activity of iron chelators: Multiple celluarl targets and the different mechanism of action of Triapine compared with Desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin. Cancer Res. 2003, 9, 402-414.
16. (b) Finch, R. A.; Liu, M.-C.; Grill, S. P. Triapine (3-aminopyridine-2- carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol. 2000, 59, 983-991.
17. (c) Cory, J. G.; Cory, A, H.; Rappa, G.; Lorico, A.; Liu, M. C.; Lin, T. S.; Sartorelli, A. C. Inhibitors of ribonucleotides reductase. Comparative effects of amino- and hydroxy substituted pyridne-2-carboxaldehyde thiosemicarbazones. Biochem. Pharmacol. 1994, 48, 335-344.
18. (a) Richardson, D. R.; Tran, E. H.; Ponka, P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 1995, 86, 4295-4306.
19. (b) Ponka, P.; Borlva, J.; Neuwirt, J.; Fuchs, O. Mobilization of iron from reticulocytes, identification of pyridoxal isonicotinoly hydrazone as a new iron chelating agent. FEBS Lett. 1979, 97, 317-321.
20. Bowen, T.; Planalp, R. P.; Brechbiel, M. W. An improved synthesis of cis,cis-1,3,5-triaminocyclohexane. Synthesis of novel hexadentate ligand derivatives for the prepartion of gallium radiopharmaceuticals. Bioorg. Med. Chem. Lett. 1996, 6, 807-809.
21. (a) Torti, S. V.; Torti, F. M.; Whitman, S. P.; Brechbiel, M. W.; Park, G.; Planalp, R. P. Tumor cell cytotoxicity of a novel metal chelator. Blood 1998, 92, 1384-1389.
22. (b) Abeysinghe, R. D.; Greene, B. T.; Haynes, R.; Willingham, M. C.; Turner, J.; Planalp, R. P.; Brechbiel, M. W.; Torti, F. M.; Torti, S. V. p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Carcinogenesis 2001, 22, 1607-1614.
23. (c) Greene B. T.; Thorburn, J.; Willingham, M. C.; Thorburn, A.; Planalp R. P.; Brechbiel, M. W.; Jennings-Gee, J.; Wilkinson, J., IV; Torti, F. M.; Torti, S. V. Activation of caspase pathways during iron chelator-mediated apoptosis. J. Biol. Chem. 2002, 277, 25568-25575.
24. (d) Planalp, R. P., Przvborowska, A. M., Park, G., Ye, N., Lu, F. H., Rogers, R. D., Broker, G. A., Torti, S. V., Brechbiel, M. W. Novel cytotoxic chelators that bind iron(II) selectively over zinc(II) under aqueous aerobic conditions. Biochem. Soc. Trans. 2002, 30, 758-762.
25. (a) Yu, A. L.; Rak, J. W.; Coomber, B. L.; Hicklin, D. J.; Kerbel, R. S. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002, 295, 1526-1528.
26. (b) Perego, P.; Giarola, M.; Righetti, S. C.; Supino, R.; Caserini, G.; Delia, D.; Pierotti, M. A.; Miyashita, T.; Reed, J. C.; Zunino, F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. 1996, 56, 556-562.
27. (c) O'Conner, P. M.; Jackman, J.; Bae, I.; Myers, T. G.; Fan, S.; Mutoh, M.; Scudiero, D. A.; Monks, A.; Sausville, E. A.; Weinstein, J. N.; Friend, S.; Fornace, A. J., Jr.; Kohn, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997, 57, 4285-4300.
28. (d) Hollstein, M.; Rice, K.; Greenblatt, M. S.; Soussi, T.; Fuchs, R.; Sorlie, T.; Hovig, E.; Simith-Sorensen, B.; Montesano, R.; Harris, C. C. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 1994, 22, 3551-3555.
29. Chong, H. S.; Torti, F. M.; Torti, S. V.; Brechbiel, M. W. Synthesis of 1,3, 5-cis,cis-triaminocyclohexane N-pyridyl derivatives as potential antitumor agents. J. Org. Chem. 2002, 67, 8072-8088.
30. Langlois, Y.; Potier, P. Synthèse totale de la (±) descarbométhoxy-16 vobasine. Tetrahedron 1975, 31, 419-422.
31. Mosmann, T. J. Rapid colorimetric assay for celluar growth and survival: Application to proliferation and cytotoxicity assays. Immunol. Methods 1983, 65, 55-63.
32. Wu, C.; Brechbiel, M. W.; Kozak, R. W.; Gansow, O. A. Synthesis and evaluation of anti-proliferative activity of a Geldanamycin-HerceptinTM immunoconjugate. Bioorg. Med. Chem. Lett. 1994, 4, 449-454.
33. Trail, P. A.; King, H. D.; Dubowchik, G. M. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol. Immunother. 2003, 52, 328-337.
34. (a) Trail, P. A.; Willner, D.; Bianchi, A. B.; Henderson, A. J.; Trailsmith, M. D.; Giritlasch, S.; Hellstrom, I.; Hellstrom, K. E. Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin. Clin. Cancer Res. 1945, 5, 3632-3638.
35. (b) Safavy, A.; Bonner, J. A.; Waksal, H. W.; Buchsbaum, D. J.; Gillespie, G. Y.; Khazaeli, M. B.; Arani, R.; Chen, D. T.; Carpenter, M.; Raisch, K. P. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjugate Chem. 2003, 14, 302-310.